{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:25:57Z","timestamp":1773282357721,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"DOI":"10.1093\/jac\/dkl524","type":"journal-article","created":{"date-parts":[[2007,1,26]],"date-time":"2007-01-26T01:23:34Z","timestamp":1169774614000},"page":"342-346","source":"Crossref","is-referenced-by-count":99,"title":["Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors"],"prefix":"10.1093","volume":"59","author":[{"given":"Antonio","family":"Rivero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Mira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,1,25]]},"reference":[{"key":"key\n\t\t\t\t20171010225614_DKL524C1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Grade 4 events are as important as AIDS events in the era of HAART","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171010225614_DKL524C2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171010225614_DKL524C3","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"44","author":"Nu\u00f1ez","year":"2006","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171010225614_DKL524C4","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1086\/381448","article-title":"Pitfalls of assessing hepatotoxicity in trials and observational cohorts","volume":"38","author":"Sabin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C5","article-title":"Table of grading severity of adult adverse experiences","author":"AIDS Clinical Trials Group","year":"1996"},{"key":"key\n\t\t\t\t20171010225614_DKL524C6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171010225614_DKL524C7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171010225614_DKL524C8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171010225614_DKL524C9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-na\u00efve HIV-infected adults","volume":"39","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171010225614_DKL524C11","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Mart\u00ednez","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171010225614_DKL524C12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171010225614_DKL524C13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"Martin-Carbonero","year":"2003","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20171010225614_DKL524C14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study","volume":"35","author":"Manfredi","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171010225614_DKL524C15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00002030-200310170-00007","article-title":"Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996\u20132001","volume":"17","author":"Law","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C16","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Mart\u00ednez","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J Inf Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","article-title":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir","volume":"18","author":"Sulkowski","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/01.aids.0000180791.85003.3b","article-title":"Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir\/ritonavir","volume":"19","author":"Bonfanti","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C20","article-title":"Safety of a fosamprenavir\/ritonavir (FPV\/r) containing regimen over 120 weeks in HIV-1 infected therapy-na\u00efve adults with or without hepatitis B (HBV) and\/or C (HCV) co-infection","author":"DeJesus"},{"key":"key\n\t\t\t\t20171010225614_DKL524C21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jac\/dkl074","article-title":"Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir","volume":"57","author":"Pineda","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010225614_DKL524C22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171010225614_DKL524C23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171010225614_DKL524C24","article-title":"Prescribing information","author":"Sustiva (efavirenz)"},{"key":"key\n\t\t\t\t20171010225614_DKL524C25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/135965350200700202","article-title":"A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine\/lamivudine in HIV-infected na\u00efve patients (The Combine Study)","volume":"7","author":"Podzamczer","year":"2002","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171010225614_DKL524C26","first-page":"987","article-title":"A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients","volume":"17","author":"van Leeuwen","journal-title":"AIDS 2003"},{"key":"key\n\t\t\t\t20171010225614_DKL524C27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/archpedi.156.6.568","article-title":"Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children","volume":"156","author":"Melvin","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key\n\t\t\t\t20171010225614_DKL524C28","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/381453","article-title":"Liver injury during highly active antiretroviral therapy: The effects of hepatitis C coinfection","volume":"38","author":"Bonacini","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C29","doi-asserted-by":"crossref","first-page":"F203","DOI":"10.1097\/00002030-199816000-00002","article-title":"Antiretroviral effect and safety of abacavir alone and in combinations with zidovudine in HIV-infected adults","volume":"12","author":"Saag","year":"1998","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C30","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2165\/00003495-200464180-00014","article-title":"Fosamprenavir: a review of its use in the management of antiretroviral therapy-na\u00efve patients with HIV infection","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171010225614_DKL524C31","first-page":"1321","article-title":"DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy","volume":"27","author":"Bourezane","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C32","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/00002030-200310170-00009","article-title":"Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment","volume":"17","author":"de Maat","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/313629","article-title":"Hypersensitivity syndrome associated with efavirenz therapy","volume":"30","author":"Bossi","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(00)04663-8","article-title":"Pulmonary hypersensitivity reaction induced by efavirenz","volume":"357","author":"Behrens","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171010225614_DKL524C35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jinf.2005.05.020","article-title":"Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure","volume":"52","author":"Angel-Moreno-Maroto","year":"2006","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20171010225614_DKL524C36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jac\/dkf204","article-title":"Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment na\u00efve female AIDS patient without hepatitis virus co-infection","volume":"50","author":"Abrescia","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010225614_DKL524C37","article-title":"Prescribing information","author":"Viramune (nevirapine)"},{"key":"key\n\t\t\t\t20171010225614_DKL524C38","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171010225614_DKL524C39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00002030-200201250-00020","article-title":"Liver toxicity caused by nevirapine","volume":"16","author":"Gonz\u00e1lez de Requena","year":"2002","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00228-004-0769-5","article-title":"No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients na\u00efve of antiretroviral treatment or switched from protease inhibitors","volume":"60","author":"Dailly","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20171010225614_DKL524C42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/0889222041524670","article-title":"The relationship between nevirapine plasma concentrations and abnormal liver function test","volume":"20","author":"Almond","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20171010225614_DKL524C43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171010225614_DKL524C44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1258\/09564620360719840","article-title":"Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients","volume":"14","author":"Ena","year":"2003","journal-title":"Int J STD AIDS"},{"key":"key\n\t\t\t\t20171010225614_DKL524C45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jac\/dkl214","article-title":"Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C","volume":"58","author":"Mira","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171010225614_DKL524C46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171010225614_DKL524C47","article-title":"The Hepadose study: evaluation of protease inhibitors and non nucleoside analogue plasma concentrations in HIV\/HCV and HIV infected patients","author":"Dom\u00ednguez"},{"key":"key\n\t\t\t\t20171010225614_DKL524C48","article-title":"HAART-associated hepatotoxicity in HIV\/HCV-co-infected patients with cirrhosis","author":"Casado"},{"key":"key\n\t\t\t\t20171010225614_DKL524C49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-138-3-200302040-00012","article-title":"Hepatitis C in the HIV-infected person","volume":"138","author":"Sulkowski","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/59\/3\/342\/2507962\/dkl524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T13:20:47Z","timestamp":1707571247000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/59\/3\/342\/843408\/Liver-toxicity-induced-by-nonnucleoside-reverse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,25]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2007,1,25]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkl524","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,3]]},"published":{"date-parts":[[2007,1,25]]}}}